The N-terminal and central domain of colicin A enables phage lysin to lyse Escherichia coli extracellularly

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 110, Issue 12, 2017, Pages 1627-1635

  Yan, Guangmou ^a   Liu, Jianfang ^a   Ma, Qiang ^a   Zhu, Rining ^a   Guo, Zhimin ^b   Gao, Chencheng ^a   Wang, Shuang ^a   Yu, Ling ^a   Gu, Jingmin ^a   Hu, Dongliang ^a,c   Han, Wenyu ^a   Du, Rui ^d   Yang, Junling ^a,b   Lei, Liancheng ^a  

^a JILIN UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c KITASATO UNIVERSITY   (Japan)

^d JILIN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Antimicrobial resistance; Bacteriophage; Bacteriophage lysin; Escherichia coli; Gram negative bacteria

Indexed keywords

COLICIN A; HYBRID PROTEIN; MEMBRANE FUSION PROTEIN; PEPTIDOGLYCAN; COLICIN; VIRAL PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIOPHAGE LYSIN; CONTROLLED STUDY; ESCHERICHIA COLI; EXTRACELLULAR SPACE; GENE TRANSLOCATION; IN VITRO STUDY; INTESTINE INFECTION; MOUSE; MOUSE MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEPTOR BINDING; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; BACTERIOLYSIS; CHEMISTRY; COLIPHAGE; ENTERITIS; ESCHERICHIA COLI INFECTION; GENETICS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; BACTERIOLYSIS; COLICINS; COLIPHAGES; ENTERITIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICE; PROTEIN DOMAINS; VIRAL PROTEINS;

EID: 85025069399     PISSN: 00036072     EISSN: 15729699     Source Type: Journal    
DOI: 10.1007/s10482-017-0912-9     Document Type: Article

References (38)

1. Bardhan P, Faruque AS, Naheed A, Sack DA (2010) Decrease in Shigellosis-related deaths without Shigella spp.-specific interventions. Asia. Emerg Infect Dis 16:1718–1723
2. Braun V, Pilsl H, Gross P (1994) Colicins: structures, modes of action, transfer through membranes, and evolution. Arch Microbiol 161:199–206
3. Briers Y, Lavigne R (2015) Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol 10:377–390
4. Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R (2014) Engineered endolysin-based “Artilysins” to combat multidrug-resistant gram-negative pathogens. MBio 5:e01379.
5. Cascales E, Buchanan SK, Duché D, Kleanthous C, Lloubès R, Postle K, Riley M, Slatin S, Cavard D (2007) Colicin biology. Microbiol Mol Biol Rev 71:158–229
6. Cheng Q, Nelson D, Zhu S, Fischetti VA (2005) Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49:111–117
7. Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, Fauvart M, Michiels J, Lavigne R, Briers Y (2016) Efficacy of Artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother 60:3480–3488
8. Dehkordi FS, Yazdani F, Mozafari J, Valizadeh Y (2014) Virulence factors, serogroups and antimicrobial resistance properties of Escherichia coli strains in fermented dairy products. BMC Res Notes 7:217
9. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B (2015) Bacteriophages and phage-derived proteins–application approaches. Curr Med Chem 22:1757–1773
10. Fischetti VA (2008) Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11:393–400
11. Knibiehler M, Howard SP, Baty D, Geli V, Lloubès R, Sauve P, Lazdunski C (1989) Isolation and molecular and functional properties of the amino-terminal domain of colicin A. Eur J Biochem 181:109–113
12. Lazdunski CJ, Bouveret E, Rigal A, Journet L, Lloubès R, Bénédetti H (1998) Colicin import into Escherichia coli cells. J Bacteriol 180:4993–5002
13. Lazdunski C, Bouveret E, Rigal A, Journet L, Lloubès R, Bénédetti H (2000) Colicin import into Escherichia coli cells requires the proximity of the inner and outer membranes and other factors. Int J Med Microbiol 290:337–344
14. Lim JA, Shin H, Kang DH, Ryu S (2012) Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S. Res Microbiol 163:233–241
15. Loeffler JM, Nelson D, Fischetti VA (2001) Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170–2172
16. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA (2015) Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59:1983–1991
17. Lukacik P, Barnard TJ, Buchanan SK (2012a) Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis. Biochem Soc Trans 40:1503–1506
18. Lukacik P, Barnard TJ, Keller PW, Chaturvedi KS, Seddiki N, Fairman JW, Noinaj N, Kirby TL, Henderson JP, Steven AC, Hinnebusch BJ, Buchanan SK (2012b) Structural engineering of a phage lysin that targets gram-negative pathogens. Proc Natl Acad Sci USA 109:9857–9862
19. Lv M, Wang S, Yan G, Sun C, Feng X, Gu J, Han W, Lei L (2015) Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3. Virus Genes 50:487–497
20. Ma Q, Guo Z, Gao C, Zhu R, Wang S, Yu L, Qin W, Xia X, Gu J, Yan G, Lei L (2017) Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus. Antonie Van Leeuwenhoek 110:347–355
21. Majeed H, Gillor O, Kerr B, Riley MA (2011) Competitive interactions in Escherichia coli populations: the role of bacteriocins. ISME J 5:71–81
22. Moradpour Z, Ghasemian A (2011) Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 29:732–738
23. Morlon J, Lloubes R, Chartier M, Bonicel J, Lazdunski C (1983a) Nucleotide sequence of promoter, operator and amino-terminal region of caa, the structural gene of colicin A. EMBO J 2:787–789
24. Morlon J, Lloubès R, Varenne S, Chartier M, Lazdunski C (1983b) Complete nucleotide sequence of the structural gene for colicin A, a gene translated at non-uniform rate. J Mol Biol 170:271–285
25. Nandanwar N, Janssen T, Kühl M, Ahmed N, Ewers C, Wieler LH (2014) Extraintestinal pathogenic Escherichia coli (ExPEC) of human and avian origin belonging to sequence type complex 95 (STC95) portray indistinguishable virulence features. Int J Med Microbiol 304:835–842
26. Narciso-da-Rocha C, Manaia CM (2016) Multidrug resistance phenotypes are widespread over different bacterial taxonomic groups thriving in surface water. Sci Total Environ 563–564:1–9
27. Nelson D, Loomis L, Fischetti VA (2001) Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98:4107–4112
28. Oliveira H, Vilas Boas D, Mesnage S, Kluskens LD, Lavigne R, Sillankorva S, Secundo F, Azeredo J (2016) Structural and enzymatic characterization of ABgp46, a novel phage endolysin with broad anti-gram-negative bacterial activity. Front Microbiol 7:208
29. Pavlickova S, Klancnik A, Dolezalova M, Mozina SS, Holko I (2017) Antibiotic resistance, virulence factors and biofilm formation ability in Escherichia coli strains isolated from chicken meat and wildlife in the Czech Republic. J Environ Sci Health B 11:1–7
30. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J (2015) Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89:7449–7456
31. Plotka M, Kaczorowska AK, Morzywolek A et al (2015) Biochemical characterization and validation of a catalytic site of a highly thermostable Ts2631 endolysin from the thermus scotoductus phage vB_Tsc2631. PLoS ONE 10:e0137374
32. Qadir MI (2015) Review: phage therapy: a modern tool to control bacterial infections. Pak J Pharm Sci 28:265–270
33. Sande-Bruinsma NVD, Grundmann H, Verloo D, Tiemersma E, Monen J (2008) Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 14:1722–1730
34. Thandar M, Lood R, Winer BY, Deutsch DR, Euler CW, Fischetti VA (2016) Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 60:2671–2679
35. Turner SM, Scott-Tucker A, Cooper LM, Henderson IR (2006) Weapons of mass destruction: virulence factors of the global killer enterotoxigenic Escherichia coli. FEMS Microbiol Lett 263:10–20
36. Walmagh M, Boczkowska B, Grymonprez B, Briers Y, Drulis-Kawa Z, Lavigne R (2013) Characterization of five novel endolysins from Gram-negative infecting bacteriophages. Appl Microbiol Biotechnol 97:4369–4375
37. Yan M, Baran PS (2016) Drug discovery: fighting evolution with chemical synthesis. Nature 533:326–327
38. Young R, Gill JJ (2015) MICROBIOLOGY. phage therapy redux–What is to be done? Science 350:1163–1164